Gelesis Holdings, Inc.
GLS-WT
New York Stock Exchange0.01
USD
- -
- -
Gelesis Holdings, Inc.
GLS-WT
(New York Stock Exchange)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Gelesis Holdings, Inc. Gelesis Holdings, Inc. (GLS-WT) operates as a biotherapeutics company that develops superabsorbent hydrogel therapeutics for chronic gastrointestinal diseases, including obesity, type 2 diabetes, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, functional constipation, and inflammatory bowel disease; its flagship product Plenity serves as an FDA-cleared, orally administered, non-stimulant, non-systemic weight management aid inspired by the properties of raw vegetables that expands in the stomach to promote satiety; the company also advances GS200 for weight loss in prediabetes and type 2 diabetes, GS500 for functional constipation, and preclinical GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Founded in 2006 and headquartered in Boston, Massachusetts, Gelesis primarily targets overweight and obese adults as well as patients with related metabolic conditions through prescription-based consumer engagement in the United States and select international markets. In October 2023, the company, along with affiliates Gelesis, Inc. and Gelesis LLC, filed voluntary petitions for Chapter 7 liquidation in the U.S. Bankruptcy Court for the District of Delaware due to funding shortfalls following its 2022 SPAC merger and halted marketing efforts; in July 2024, the Chapter 7 trustee completed the sale of substantially all assets, including intellectual property and majority equity in an Italian manufacturing affiliate, to T-Investments S.r.l. and Andromeda Energy S.r.l.